It's always thrilling for us to hear from customers about how they are utilizing our products, especially when they are being used in research. While customers often share their uses with us upon purchasing, reading publications is another way we learn about how our reagents are helping researchers. For example, last week, researchers from Weill Cornell Medicine published protocols for the development of cancer drug discovery models using our Premium Imported Fetal Bovine Serum (Cat.# FBS002).

The ability of cancer models to truly mimic individual cancers is paramount in understanding how therapeutics can be used to treat cancer. While conventional cancer cell lines are useful models, more recently, patient derived tumor xenografts (PDTXs) have demonstrated the ability to better mimic cancer. PDTXs are models where tissue or cells from a patient’s tumor is extracted before being implanted in immunodeficient mice. By doing this, the tumor cells maintain many of the same properties as the patient’s tumor, creating a perfect model for drug discovery and therapeutics.

Image: Explanation of the overall strategy to develop PDTX models.

Read more to learn about how our FBS was used in their studies...

Over time, researchers have developed a large library of PDTXs for solid tumors, however, PDTXs development for hematological cancers has not been previously described. Through their research, the investigators have laid out protocols to establish and validate lymphoma PDTX models. In the process of transferring the cells from patient to mouse, our FBS was used to culture the cells. Hopefully, other researchers will use these models in the future making it easier to treat and even cure patients with lymphoma.



  1. Maria Teresa Cacciapuoti, Luca Vincenzo Cappelli, Danilo Fiore, Pedro Toruno, Clarisse Kayembe, Wayne Tam, and Giorgio Inghirami. (2021). In Vivo and Ex Vivo Patient‐Derived Tumor Xenograft Models of Lymphoma for Drug Discovery.Current Protocols, 1(4). doi: 10.1002/cpz1.96